Workflow
福泰制药(VRTX)
icon
搜索文档
Vertex Pharmaceuticals Incorporated (VRTX) 43rd Annual Cowen Healthcare Conference Transcript
2023-03-08 08:51
公司信息 * **公司名称**:Vertex Pharmaceuticals Incorporated (VRTX) * **行业**:生物制药 * **会议时间**:2023年3月7日 * **参会人员**:Reshma Kewalramani(总裁兼首席执行官)、Charlie Wagner(首席财务官)、Phil Nadeau(Cowen生物技术分析师) 核心观点和论据 * **公司发展**:Vertex在囊性纤维化(CF)领域取得显著进展,目前涉足8个疾病领域,包括CF、镰状细胞性贫血、β-地中海贫血、急性疼痛、神经性疼痛、1型糖尿病、APOL1介导的肾脏病和AATD。 * **财务状况**:公司资产负债表强劲,能够将资金重新投资于创新。 * **未来目标**:到2030年,公司将继续执行其计划,包括在CF领域保持领导地位,扩大CF产品组合,并推进其他疾病领域的研发。 * **CF产品**:TRIKAFTA预计将继续实现显著增长,Vanza三联疗法有望成为下一代疗法。 * **其他产品**:Exa-cel、VX-548、AMKD、VX-880等产品的研发进展顺利。 其他重要内容 * **CF患者人数**:全球CF患者人数估计为88,000人,比五年前增加了13,000人。 * **TRIKAFTA**:预计将于2023年4月获得2-5岁儿童的批准。 * **Exa-cel**:预计将于2023年4月在美国完成滚动BLA提交。 * **VX-548**:预计将于2023年底或2024年初完成III期临床试验。 * **AMKD**:预计将于2023年完成II/III期临床试验。 * **VX-880**:已证明对1型糖尿病具有治疗潜力,正在进行临床试验。 总结 Vertex Pharmaceuticals Incorporated在生物制药领域取得了显著进展,其产品组合涵盖了多个疾病领域。公司预计将继续实现显著增长,并在未来几年内推出更多新产品。
Vertex(VRTX) - 2022 Q4 - Annual Report
2023-02-10 00:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 04-3039129 (State or other jurisd ...
Vertex(VRTX) - 2022 Q4 - Earnings Call Transcript
2023-02-08 10:10
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2022 Earnings Conference Call February 7, 2023 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Reshma Kewalramani - Chief Executive Officer and President Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Geoff Meacham - Bank of America Phil Nadeau - Cowen Liisa Bayko - Evercore ISI David Risinger - SVB Robyn Karnauskas - Tru ...
Vertex(VRTX) - 2022 Q4 - Earnings Call Presentation
2023-02-08 07:09
FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS ©2023 Vertex Pharmaceuticals Incorporated VERTEX FEBRUARY 7, 2023 AGENDA Introduction Susie Lisa, CFA, Senior Vice President, Investor Relations CEO Perspective and Pipeline Update Reshma Kewalramani, M.D., Chief Executive Officer and President Commercial Update Stuart Arbuckle, Executive Vice President and Chief Operating Officer Financial Results Charlie Wagner, Executive Vice President and Chief Financial Officer ©2023 Vertex Pharmaceuticals Incorporate ...
41st Annual J.P. Morgan Healthcare Conference
2023-01-10 02:06
VERTEX THE SCIENCE of POSSIBILITY J.P. MORGAN HEALTHCARE CONFERENCE RESHMA KEWALRAMANI, M.D. CEO AND PRESIDENT JANUARY 2023 ©2023 Vertex Pharmaceuticals Incorporated global.vrtx.com | --- | --- | --- | --- | --- | |--------------------------------------------|-------|----------|-------|-------| | | | | | | | SAFE HARBOR STATEMENT & NONGAAP FINANCIAL | | | | | | | | MEASURES | | | | | | | | | | | | | | | | ©2023 Vertex Pharmaceuticals Incorporated | | | | | This presentation contains forward-looking statemen ...
Vertex Pharmaceuticals Incorporated (VRTX) 41st Annual J.P. Morgan Healthcare Conference - (Transcript)
2023-01-10 02:04
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 41st Annual J.P. Morgan Healthcare Conference Call January 9, 2023 11:15 AM ET Company Participants Reshma Kewalramani - Chief Executive Officer and President Charlie Wagner - Chief Financial Officer Stuart Arbuckle - Chief Operating Officer David Altshuler - Executive Vice President, Global Research, and Chief Scientific Officer Conference Call Participants Jessica Fye - J.P. Morgan Jessica Fye Great. Good morning, everyone. Welcome. I'm Jessica Fye. I'm a ...